Anxiety-related disorders affect a huge segment of our population — 40 million adults (18%) in the United States age 18 and older. In response, Big Pharma has developed numerous drugs to treat anxiety-related disorders, from selective serotonin reuptake inhibitors (SSRIs) like Prozac and Zoloft to tranquilizers (the most popular class being benzodiazepines such as Valium and Xanax).
While these drugs can be effective for many patients, some don’t respond favorably. Certain patients don’t see much improvement, or they can’t tolerate the side effects. Moreover, tranquilizers like Valium and Xanax can be highly addictive.
Clearly, alternative treatments are warranted. Could cannabidiol (CBD), the most prominent non-psychoactive constituent in cannabis/hemp, provide a viable alternative for currently available anxiety medications? Quite possibly!
Mental Health Daily has quoted that: “While it is impossible to confirm that CBD will effectively reduce anxiety in all users, most evidence indicates that it is likely to provide benefit when ingested at a sufficient dosage (600 mg – orally) on an acute basis.
In other words, most people seeking immediate relief from anxiety will likely feel significantly less anxious after using CBD than if they had ingested a placebo. Placebo-controlled studies have already documented the efficacy of acute CBD administration for anxiety.”
Through studies it has been found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing.
Likewise, evidence from human studies supports an anxiolytic (a medication or other intervention that inhibits anxiety) role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.